DNDi is a not-for-profit drug development initiative established in 2003 by four publicly-funded research organisations - Kenya Medical Research Institute, Indian Council for Medical Research, Oswaldo Cruz Foundation Brazil, Malaysian Ministry of Health; a private research institute, the Institut Pasteur; an international research organisation WHO's Tropical Diseases Research programme; and an international humanitarian organisation Médecins Sans Frontières.

DNDi aims to develop new, improved and field-relevant drugs for neglected diseases such as leishmaniasis, human African trypanosomiasis, and Chagas disease that afflict the very poor in developing countries. It will raise awareness of the urgent need to develop drugs for these diseases and use DNDi projects to strengthen existing capacity in disease-endemic countries.

Combination Therapy in Global Strategy for Treatment of Malaria

Every year, malaria kills 1-2 million people. 90% of deaths occur in sub-Saharan Africa. The disease is present in over 100 countries and threatens 40% of the world population.

See also:

DNDi-Sanofi Aventis sign agreement on AS/AQ

DNDi has developed a fixed-dose formulation of artesunate amodiaquine (AS/AQ) for the treatment of malaria. This combination has the two drugs, artesunate and amodiaquine, in one tablet...

Canton of Geneva commits 200,000CHF to DNDi East Africa Project

The Canton of Geneva has committed an initial 200,000 CHF to the DNDi-LEAP Paromomycin Clinical Trial in Sudan, Ethiopia and Kenya for visceral leishmaniasis. The objective of this project is to make a more effective, shorter course, less toxic treatment...

DNDi's Scientific Advisory Committee

Drug development pipeline

In keeping with its R&D strategy, DNDi hopes to build a mixed balanced pipeline of short, medium and long term projects...

Meet Nubia Boechat,
MSc, PhD